Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bill Highlights
Legislation Targets FDA User Fee And Regulatory Reform
by Britt E. Erickson
May 21, 2012
| A version of this story appeared in
Volume 90, Issue 21
Congress is working to combine multiple actions related to drugs into a single bill. First, the legislation aims to authorize the Food & Drug Administration to collect user fees from the drug and medical device industry for five years. Second, it includes several regulatory reform measures related to drug safety and development.
The House of Representatives and Senate are expected to vote on the package this month with the goal of sending a compromise measure to the President by the end of June. Current user fee programs expire Sept. 30. The following are highlights of the pending legislation:
The bill reauthorizes
◾ The Prescription Drug User Fee Act (PDUFA), under which industry will pay $713 million in fiscal 2013; higher amounts will be incurred in the remaining four years.
◾ The Medical Device User Fee & Modernization Act, under which industry pays $595 million over five years.
◾ The Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, which provide incentives for studies on the effects of prescription drugs and medical devices on children.
The bill establishes
◾ The Generic Drug User Fee Act, under which industry pays $1.5 billion over five years in return for faster and more predictable review of generic drug applications and increased inspections of drug facilities.
◾ The Biosimilars User Fee Act, which includes four types of fees for biosimilar products: application, product, establishment, and product development. The first three would be set equal to the PDUFA rate for each type of fee, and the product development fee would be set at 10% of the PDUFA application fee.
The bill reforms
◾ Conflict-of-interest rules at FDA by loosening them to ensure that the most knowledgeable experts can serve on FDA’s scientific advisory committees.
◾ The drug approval pathway by increasing access to the accelerated pathway, particularly for drugs that treat rare diseases; by providing incentives for developing antibiotics; and by addressing increased globalization of drug manufacturing.
◾ Reporting requirements for disruptions in production of lifesaving drugs and modifies the process to expedite approval of drugs in short supply.
Advertisement
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter